Compare Gilead Sciences, Inc. (GILD) vs Direxion Daily S&P 500 Bull 3X Shares (SPXL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Direxion Daily S&P 500 Bull 3X Shares — how do they compare? Gilead Sciences, Inc. trades at $132.9 (market cap $163.51B), while Direxion Daily S&P 500 Bull 3X Shares trades at $277.45. The key difference: Gilead Sciences, Inc. pays a 2.49% dividend while Direxion Daily S&P 500 Bull 3X Shares pays none, and Direxion Daily S&P 500 Bull 3X Shares is trading nearer its 52-week high, Gilead Sciences, Inc. nearer its low. Which is the better fit depends on your goals.
| GILD | SPXL | |
|---|---|---|
Market Cap | $163.51B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $155.80 | $288.04 |
52-Week Low | $108.22 | $170.20 |
Enterprise Value | $178.05B | — |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $130.04, down 1.04% on the day, with technical indicators showing a bearish bias while fundamentals remain strong. The company has beaten earnings expectations for three consecutive quarters, maintains robust profitability with a 30.99% net income margin, and recently secured FDA and European Commission approvals for expanded use of its oncology drug Trodelvy. Analyst consensus remains overwhelmingly positive with a $152.83 price target representing 17.5% upside potential.
The outlook for GILD is favorable with strong earnings momentum, expanding oncology portfolio, and solid cash generation, though risks include patent expirations, competitive pressures in HIV treatments, and recent negative cash flow trends. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharmaceutical company with growth catalysts, supported by Wall Street's bullish sentiment and recent regulatory wins.
SPXL, a leveraged ETF tracking the S&P 500, trades at $277.94, up 0.84% on the day, with a bullish technical stance from moving averages and neutral oscillators. The S&P 500 index nears all-time highs amid AI-driven optimism and earnings season catalysts. Recent news highlights potential resistance near 7,620 and bullish year-end targets from analysts like Tom Lee (8,000) and Lori Calvasina (8,150).
Outlook remains positive with AI infrastructure spending and earnings momentum as key drivers, but risks include stretched valuations, Fed policy uncertainty, and geopolitical tensions. Investors should weigh the leveraged nature of SPXL against potential volatility during market corrections.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Direxion Daily S&P 500 Bull 3X Shares
SPXL aims for 300% of the S&P 500's daily performance. It uses swaps and futures to provide 3x leverage, making it a high-risk tool for short-term traders. Due to daily resets, it is prone to volatility decay and is not intended for long-term holding.
Read more on SPXL →
